![]() |
|
|
Vol. 301, Issue 1, 15-20, April 2002
Department of Cardiovascular Pharmacology, GlaxoSmithKline, King of Prussia, Pennsylvania
| |
Abstract |
|---|
|
|
|---|
The vascular response to mechanical injury involves inflammatory and
fibroproliferative processes that result in the formation of neointima
and vascular remodeling. The complex cellular interactions initiated by
vascular injury are coordinated and modulated by the elaboration of
cytokines and growth factors. The production and transduction of many
of these mediators require phosphorylation of p38 mitogen-activated
protein kinase (MAPK). In the present investigation, we examined the
pattern and localization of p38 MAPK activation following balloon
vascular injury. The effects of long-term and selective inhibition of
p38 MAPK with SB 239063 (trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[2-methoxy)pyrimidin-4-yl]imidazole) were also investigated in a model of vascular injury. Western blotting
and immunohistochemical staining demonstrated that phospho-p38 MAPK was
increased following balloon injury of the rabbit iliofemoral artery.
The p38 MAPK activation was noted as early as 15 min after balloon
injury and remained elevated for at least 28 days. Phospho-p38 MAPK
immunoreactivity (IR) was localized primarily in regions of
dedifferentiated, smooth muscle
-actin-positive cells in all lamina
of the vessel wall. Phospho-p38 MAPK IR was not correlated with the
localization of macrophage or proliferating cells (proliferating cell
nuclear antigen; PCNA +). Long-term treatment (4 weeks) with SB 239063 (50 mg/kg/day, p.o.) reduced the vascular response to injury in
the hypercholesterolemic rabbit. SB 239063 had no effect on
platelet-derived growth factor (PDGF)-stimulated migration or
proliferation of rabbit vascular smooth muscle cells (VSMCs) in
culture. However, SB 239063 produced a concentration-dependent inhibition of transforming growth factor (TGF)-
-stimulated
fibronectin production in VSMCs. In conclusion, sustained activation of
p38 MAPK plays an important role in the vascular response to injury and
inhibition of p38 MAPK may represent a novel therapeutic approach to
limit this response.
| |
Introduction |
|---|
|
|
|---|
The vascular response to
mechanical injury involves inflammatory and fibroproliferative
processes that result in vascular remodeling and the development of
neointima (Ferns and Avades, 2000
). Under the best circumstances, the
complex cellular interactions are highly coordinated and result in a
stable/benign vascular lesion complete with compensatory remodeling of
the thickened vessel wall and preservation of lumen (Ross, 1993
; Owens,
1995
). However, factors such as severe mechanical injury and
hypercholesterolemia may adversely influence the magnitude and temporal
pattern of cellular events, as well as the gross morphology of the lesion.
Numerous cell types are activated during this wound healing response
according to a well defined progression of events. Cells activated
following vascular injury include platelets, neutrophils, monocytes/macrophages, T-lymphocytes, endothelial cells, VSMCs, and
fibroblasts (Ross, 1993
; Ferns and Avades, 2000
). The p38 mitogen-activated protein kinase (MAPK) pathway has been shown to play
an important role in the chemical and/or mechanical stress response of
all these cell types (Junger et al., 1998
; Hackeng et al., 1999
;
Herlaar and Brown, 1999
; Li et al., 2000
). In particular, the
activation of the p38 MAPK pathway plays an important role in the
generation of numerous proinflammatory cytokines including interleukin-1 (IL-1), IL-6, IL-8, and tumor necrosis factor-
(TNF-
) (Lee et al., 1994
, 2000
). In addition, the p38 MAPK pathway also plays an important role in mediating cellular signal transduction of proinflammatory cytokines, growth factors, and hormones acting at
G
q-protein-coupled receptors (Widmann et al., 1999
; Wang et al.,
2000
). However, the majority of current studies have been limited to
the study of transient activation of p38 MAPK in cultured cells.
Information regarding the activation and inhibition of p38 MAPK in the
intact animal model is limited.
We hypothesize that p38 MAPK is activated in the vascular wall by
mechanical injury and the subsequent response to injury, and the
actions mediated by p38 MAPK play an important role in the development
of the vascular lesion. Recent evidence suggests that p38 MAPK
inhibitors reduce neointimal formation following endothelial denudation
in the rat carotid artery (Ohashi et al., 2000
). In the present study,
we examined the temporal profile and localization of activated p38 MAPK
in injured blood vessels in rabbit. Long-term treatment with a
selective p38 MAPK inhibitor, SB 239063, was also examined in a
hypercholesterolemic rabbit model of vascular injury. Mechanistic
studies were carried out to investigate the role of p38 MAPK in VSMCs
proliferation, migration, and fibronectin production.
| |
Materials and Methods |
|---|
|
|
|---|
Rabbit Balloon Angioplasty.
A total of 94 male New Zealand
White rabbits were used in the current study. In the initial study, the
temporal pattern of phospho-p38 MAPK was examined in blood vessels
obtained following balloon injury in rabbits on a normal chow diet
(n = 21). Balloon injury was performed in the left or
right iliofemoral artery, and sham operations were performed in the
opposing artery. Briefly, a 3.0 French Fogarty balloon catheter
(Baxter, Deerfield, IL) was introduced into the caudal femoral
artery and advanced to the iliac bifurcation. The balloon was inflated
from 0.09 to 0.11 ml while being pulled with a twisting motion through
the iliofemoral artery. This procedure was repeated three times. In the
second study, balloon injury was performed similarly in rabbits (3 kg, 3-4 months old) 1 week after introduction of a high fat/cholesterol diet containing 2.5% peanut oil and 0.5% cholesterol (TD 98263; Harlan Teklad, Madison, WI). Rabbits in the group were maintained on a
high fat/cholesterol diet until the end of the study. A total of 39 hypercholesterolemic rabbits were used for a time course analysis of
p38 MAPK activation by Western blotting (n = 3 per time
point) and immunohistochemical staining (n = 3 per time
point). Immunolocalization of phospho-p38, smooth muscle
-actin,
proliferating cell nuclear antigen (PCNA) and macrophage RAM-11
were performed in this group. In the third (treatment) study, a total
of 34 rabbits received a selective p38 MAPK inhibitor (SB 239063, 50 mg/kg/day, p.o., n = 18) or vehicle group (5%
hydroxypropyl-
-cyclodextrin, n = 16) for 30 days.
The chemical structure of SB 239063 has been published (Underwood et
al., 2000
). The treatment was started 2 days prior to the angioplasty
procedure. The dosing regimen, based on previous exposure studies (not
shown), was designed to achieve SB 239063 plasma levels >400 ng/ml.
All animals were euthanized at specified time points with Fatal Plus
(0.33 ml/kg; Vortech Pharmaceuticals, Dearborn, MI) and arteries were
fixed in situ by perfusion fixation at 90 mm Hg. All experiments were
conducted in accordance with the Guide for Care and Use of Laboratory
Animals (National Institutes of Health, Publication 85-23).
Tissue Extraction and Western Blot Analysis.
Protein
extracts of the iliofemoral artery were prepared for the examination
phospho-p38 MAPK expression. The iliofemoral arteries were excised at
various times after sham or balloon injury (n = 3 per
time point). Immediately after dissection, the tissues were snap frozen
in liquid nitrogen and stored at
80°C until all the samples from
the time course were collected. For extraction, iliofemoral arteries
were weighed and pulverized with a mortar and pestle. The tissues were
then homogenized and incubated in an extraction buffer consisting of 20 mM HEPES (pH = 7.4), 75 mM NaCl, 20 mM
-glycerophosphate, 100 mM Na3VO4, 0.4 mM
phenylmethylsulfonyl fluoride, 0.1 mM EDTA, 0.5 mM
dithiothreitol, 2.5 mM MgCl2, 0.1% Triton X-100,
and complete protease inhibitors while gently rotating at 4°C for 15 min. The concentration of the initial extraction mixture for each
tissue sample was normalized to 400 mg/ml. After the extraction was
complete, the samples were centrifuged at 14,000g for 20 min
at 4°C and the supernatants were collected. To check the quality and
uniformity of each extraction throughout the study, samples of each
extract were analyzed by running on SDS-polyacrylamide gel
electrophoresis (Bio-Rad, Hercules, CA) and staining with 0.25%
Coomassie Brilliant Blue 250 (Sigma-Aldrich, St. Louis, MO). Protein
concentration for each sample was determined with the DC Protein Assay
(Bio-Rad). For Western blotting, 30 µg of protein was resolved in
10% SDS-polyacrylamide gel electrophoresis precasted gel and
transferred to polyvinylidene difluoride membrane. After blocking, the
membrane was incubated with primary antibodies in Tris-buffered
saline/Tween 20 buffer overnight at 4°C followed by incubating with
horseradish peroxidase-conjugated secondary antibodies at room
temperature for 1 h. Primary antibodies included phospho-p38
(1:1000; Cell Signaling Technology Inc., Beverly, MA), p38 MAPK
(1:1000; Cell Signaling Technology Inc.) and glyceraldehyde-3-phosphate dehydrogenase (1:200; Chemicon International, Temecula, CA).
Immunoreactive bands were detected using chemiluminescence (Amersham
Biosciences, Piscataway, NJ).
Immunohistochemical Staining.
Slides were deparaffinized,
rehydrated, and placed in phosphate-buffered saline with 0.1% Tween
20. Sections were stained using streptavidin-horseradish peroxidase
labeling system on the DAKO Autostainer (Carpenteria, CA). Briefly, the
slides were exposed to 3% hydrogen peroxide for 15 min. Normal serum
at 1:50 was used to block nonspecific binding. Sections were incubated
with primary antibodies for 45 min followed by a 30-min incubation with
biotinylated secondary antibodies. Slides were incubated in 1:200
dilution of streptavidin-horseradish peroxidase (DAKO) for 15 min
followed by incubation with substrate 3',3'-diaminobenzidine for 5 min. The slides were counterstained with hematoxylin, dehydrated, and coverslipped. All primary antibodies used were monoclonal antibody and
included phospho-p38 MAPK at 1:10 dilution (Sigma-Aldrich), macrophage
RAM-11 at 1:50 dilution (DAKO),
-actin at a concentration of 2.5 µg/ml (Roche Diagnostics GmbH, Mannheim, Germany), and PCNA at 1:50
dilution (Chemicon International).
Elastin Van Gieson Staining and Morphometric Analysis. For histological evaluation of the iliofemoral arteries, a 1-cm section of iliofemoral artery was fixed in 10% neutral buffered formalin (Sigma-Aldrich) and then embedded in paraffin. Slides were deparaffinized, rehydrated, and placed in phosphate-buffered saline. Sections were stained in a solution containing hematoxylin, ferric chloride, and Lugol's iodine for 15 min. Slides were differentiated in 2% ferric chloride and treated with 5% sodium thiosulfate followed by staining in Van Gieson solution for 5 min. Slides were dehydrated, cleared, and coverslipped. The morphometric analysis of lesions was performed using Image Pro Plus image analysis software (MediaCybernetics, Inc., Silver Spring, MD). Measurements from four nonoverlapping fields from each of four vessels were obtained using 20× magnification on an Olympus microscope (Olympus, Tokyo, Japan).
Primary Culture of VSMCs from Rabbit Iliofemoral
Arteries.
An explant method was used to generate primary culture
of VSMCs (Simari et al., 1996
). Briefly, the iliofemoral artery was isolated from male New Zealand White rabbit, and adventitial connective tissue was removed under a microscope. The artery was cut open longitudinally, and endothelial cells were removed by gently scraping the lumen side with a scalpel blade. The iliofemoral artery then was
cut into 1- to 2-mm sections and plated in a culture dish supplied with
DMEM (Invitrogen, Carlsbad, CA) containing 20% FBS and 100 units/ml penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml
amphotericin B. The explants were incubated in a humidified incubator
at 37°C with 5% CO2. Initial migration (first
phase of migration) of VSMCs was observed between 5 and 6 days. To
minimize the contamination of fibroblast, only those cells from the
second to fourth phase of migration were used. VSMCs were maintained in
DMEM with 10% FBS, and cells from passages 2 to 4 were used in the
current study. VSMCs were confirmed by positive staining of
-actin.
Proliferation Assay. VSMCs from passages 2 to 4 were used in the experiments. Cells were seeded at 5000 cells/well in a 96-well plate in DMEM containing 10% FBS. Cells were allowed to adhere and grow until about 90% confluent. After being serum starved for 48 h in serum-free DMEM, the quiescent cells were stimulated with platelet-derived growth factor (PDGF) or FBS in the absence or presence of a specific p38 inhibitor, SB 239063, at 3 or 10 µM concentrations for 48 h. Medium was replaced with new DMEM containing PDGF, SB 239063, or vehicle after the first 24 h. Ten microliters of cell proliferation reagent WST-1 was added to each well according to the manufacturer's instruction (Roche Diagnostics GmbH). The absorbance of the samples against background control was read at 440 nm in a plate reader (SPECTRA MAX 250; Molecular Devices, Menlo Park, CA) after 1 to 2 h of incubation at 37°C.
Migration Assay. The migration of VSMCs was quantified using a 96-well transwell culture chamber (Neuro Probe, Gaithersburg, MD). The lower wells were loaded with 32 µl of DMEM containing 60 ng/ml PDGF or vehicle as control to give a positive meniscus. VSMCs migrated from the upper to the lower chamber through a polycarbonate filter with 8-µm pores. VSMCs were labeled with a fluorescent dye calcein-acetoxymethyl ester before it was trypsinized and counted. A total of 10,000 cells in 52 µl were plated in the upper chamber. SB 239063 or vehicle was added into upper and lower chambers to reach a final concentration of 3 and 10 µM. After a 4-h migration at 37°C, the filter was removed, and cells on the upper side of the filter were removed and those in the lower side of the filter were quantified with a Fluoroskan Ascent (Labsystems, Helsinki, Finland).
Fibronectin Synthesis in Rabbit Vascular Smooth Muscle
Cells.
VSMCs were cultured in 100-mm dishes and allowed to reach
100% confluence. The cells were serum-starved for 48 h followed by stimulation with transforming growth factor
1 (TGF-
1) 10 ng/ml
for 48 h with or without SB 239063 (0.3, 1, 3, and 10 µM). Cells
were harvested, and the proteins were extracted (in cell lysis buffer
containing 20 mM HEPES (pH = 7.4), 50 mM
-glycerophosphate, 2 mM EDTA, 10% glycerol, 0.1% Triton X-100, 1 mM dithiothreitol, 50 mM
NaF, 0.4 mM phenylmethylsulfonyl fluoride, and 1 mM
Na3VO4). Western blot
analysis was performed using a monoclonal anticellular fibronectin
antibody (Chemicon International) in a 1:1000 dilution as primary
antibody; a horseradish peroxidase-conjugated goat-anti-mouse IgG
antibody in 1:5000 dilution was used as secondary antibody. A cell
lysate from human foreskin fibroblasts (Santa Cruz Biotechnology, Santa
Cruz, CA) was used as a positive control.
Statistical Analysis.
All data are expressed as the
mean ± S.E.M.. Student's t test was used for
comparison between the SB 239063-treated and vehicle-treated groups.
Multiple comparisons were made using an analysis of variance for
unpaired data followed by post hoc analysis with the Bonferroni correction for multiple comparisons. A probability level of
P
0.05 was considered to be statistically
significant. All statistical analyses were done using InStat (GraphPad
Software, San Diego, CA).
| |
Results |
|---|
|
|
|---|
Activation of p38 MAPK after Balloon Injury.
Phospho-p38 was
examined by Western blot analysis to determine activation of p38 MAPK
after injury of the rabbit iliofemoral artery. A general pattern of p38
MAPK activation was noted in injured versus contralateral sham arteries
(n = 3 per time point) throughout the 28-day study
(Fig. 1). The increase in phospho-p38 MAPK was first noted at 15 min and remained elevated through 28 days in
injured arteries. The total p38 MAPK protein was also elevated only at
later time points following balloon injury. Phospho-p38 MAPK,
normalized to the total p38 MAPK, remained elevated when compared with
sham-injured vessels. This pattern of persistent p38 MAPK
activation was confirmed by examining phospho-p38 MAPK immunoreactivity
(IR) in sham and injured arterial sections. Prominent nuclear staining
of phospho-p38 MAPK IR was noted only in injured arteries. Phospho-p38
MAPK IR cells were first noted in the medium and adventitia
(Fig. 2). The phospho-p38 MAPK IR was
predominant in the developing neointima throughout 28 days. Phospho-p38
MAPK IR was restricted to what appeared to be rounded dedifferentiated VSMCs, whereas elongated differentiated (contractile) VSMCs in the
medium or neointima showed little or no phospho-p38 MAPK IR (Fig.
3). The temporal profile of phospho-p38
MAPK IR did not correlate with the abbreviated course of cellular
proliferation (PCNA IR), which reached a maximum between 3 and 7 days
(Fig. 4). Phospho-p38 MAPK IR also did
not correlate with the localization of macrophage/foam (RAM-11 IR)
cells (Fig. 4).
|
|
|
|
Effects of p38 MAPK Inhibition on the Vascular Response to Balloon
Injury.
SB 239063 is a potent and selective p38 MAPK inhibitor
(Table 1), and preliminary studies
indicated that plasma levels of SB 239063 >400 ng/ml are sufficient to
abolish TNF-
generation in whole blood stimulated with
lipopolysaccharide (0.1 µg/ml). The plasma concentration of SB 239063 (50 mg/kg/day) in the present study was 470 ± 84 ng/ml (Fig.
5). Plasma levels of SB 239063 did not
differ significantly on study days 0, 7, 14, or 28.
|
|
|
|
Effect of p38 MAPK Inhibition on Rabbit VSMCs Migration,
Proliferation, and Fibronectin Synthesis.
In an effort to examine
p38 MAPK-dependent mechanisms of altering the vascular lesion, we
examined the effects of SB 239063 on rabbit VSMCs migration,
proliferation, and fibronectin synthesis. Based on our pilot
proliferation and migration assays, an ED50 concentration of PDGF was employed in the current study. SB 239063 (0.1-10 µM) had no significant effect on PDGF-induced migration or
proliferation of cultured VSMCs derived from the rabbit iliofemoral artery (Fig. 7, A and B). In addition, SB
239063 did not have any significant effect on VSMCs proliferation and
migration induced by 1 and 3% FBS (data not shown). The concentration
of SB 239063 that we used in the current experiment has been shown to
significantly inhibit cytokine production induced by lipopolysaccaride
in cellular assays (Underwood et al., 2000
).
|
stimulation (Fig. 8). The
IC50 of SB239063 was in the range of 1 to 3 µM,
and the maximum efficacy of SB 239063 produced 40 to 50% inhibition of
the TGF-
-induced fibronectin production at 3 µM.
|
| |
Discussion |
|---|
|
|
|---|
Despite advances in interventional coronary techniques, late
luminal loss continues to limit the efficacy of balloon
angioplasty/stent procedures. In the present study, we have evaluated
the role of p38 MAPK in the vascular response to balloon injury.
Evidence suggests that p38 MAPK is involved in a variety of cellular
responses including cytokine production, proliferation, and migration.
Activation of p38 MAPK (phosphorylation), mediated by "upstream"
signaling kinases MKK6 or 3, participates in signal transduction
initiated by a variety of cytokines, growth factors, and
G-protein-coupled receptors, as well as chemical and mechanical
cellular stress (Widmann et al., 1999
). For example, growth factors
including PDGF, TGF-
1, basic fibroblast growth factor, and
inflammatory cytokines, such as TNF-
and IL-1, all activate p38 MAPK
and are also increased in balloon-injured blood vessels (Ferns and
Avades, 2000
; Chamberlain et al., 2001
; Chin et al., 2001
). In
addition, p38 MAPK mediates the production of a variety of cytokines
via transcriptional and post-transcriptional mechanisms. Thus, p38 MAPK
appears to play a critical role in the production and transduction of
cytokines that are believed to coordinate the vascular response to injury.
Using immunoblotting and immunohistochemical techniques, we have identified a sustained activation of p38 MAPK (phosphorylation) in balloon-injured blood vessels at all time points examined (up to 28 days). In addition, total p38 MAPK was also up-regulated at later time points after balloon injury. The increase in phospho-p38 MAPK and total p38 MAPK is perhaps not surprising given the attendant changes in cellularity and cellular phenotype observed in the progressing neointima. Thus, the up-regulation of phospho-p38 MAPK in the early phase of post-balloon injury is mainly due to the increase in phosphorylation of p38 MAPK. The combination of up-regulation of p38 protein and increased phosphorylation of p38 is the cause of overall up-regulation of phospho-p38 in the later phase.
The regional localization of phospho-p38 MAPK in the injured vessel
wall did not parallel cellular proliferation, macrophage invasion, or
foam cell accumulation. In addition, phosphorylated p38 MAPK was not
observed in fusiform VSMCs (differentiated/contractile phenotype).
Rather, phosphorylated p38 MAPK was localized to the neointima and
medium in regions of rounded synthetic VSMCs (Thyberg, 1998
). The dense
nuclear staining observed was consistent with nuclear translocation of
phospho-p38 MAPK.
Long-term treatment (4 weeks) with an orally active and selective p38
MAPK inhibitor (SB 239063) reduced the complex vascular lesion induced
by balloon injury in the hypercholesterolemic rabbit. SB 239063 treatment preserved the lumen area neointimal/medium ratio in the
injured iliofemoral arteries. Our results are consistent with a very
recent report showing that another p38 MAPK inhibitor, FR167653,
reduced neointima formation induced by balloon injury in rat carotid
arteries (Ohashi et al., 2000
). These data strongly suggested that
activation of p38 MAPK plays an important role in the vascular response
to balloon injury.
The mechanisms by which p38 MAPK inhibitors attenuate neointimal
hyperplasia appear to be complex. For example, PDGF is increased at the
site of vascular injury, and it is believed to play an important role
in neointimal development by mediating cellular proliferation and
migration. However, selective inhibition of p38 MAPK did not inhibit
PDGF-induced VSMCs proliferation and migration in vitro. Recent studies
performed in the rat suggest that inhibitors of p38 MAPK may act to
reduce neointimal hyperplasia by inhibiting interleukin-1
production
(Ohashi et al., 2000
). In the present study, p38 MAPK inhibition also
produced a concentration-related reduction in fibronectin production
induced by TGF-
in VSMCs. Similar effects on fibronectin gene
expression have been observed in A498 renal epithelial cells where p38
MAPK inhibitors selectively reduced TGF-
induction of fibronectin
expression, but not collagen expression (N. J. Laping, personal
communication). The decrease in fibronectin expression correlated well
with inhibition of p38 MAPK activity as evidenced by inhibition of
ATF-2 phosphorylation in the A498 cells (N. J. Laping, personal
communication). Thus, the p38 MAPK signaling pathway appears to play a
critical role in TGF-
stimulated fibronectin expression as well as
cytokine production.
Fibronectin plays an important role in development and wound healing by
mediating a variety of cellular processes, i.e., differentiation, migration, and proliferation (Potts and Campbell, 1996
). Following balloon injury in blood vessels, an early and sustained fibronectin gene and protein expression are observed (Kim et al., 1995
; Thyberg et
al., 1997
). A similar expression profile has been observed for the
fibronectin integrin receptor,
5
1, and the
fibronectin stimulant, TGF-
, and all are localized to the developing
neointima (Kim et al., 1995
; Pickering et al., 2000
). Fibronectin, like phospho-p38 MAPK, is associated with synthetic VSMCs in the neointima (Thyberg, 1998
), where it is believed to regulate the VSMCs
phenotype (Hedin and Thyberg, 1987
). Fibronectin interactions with
5
1-mediated migration, via focal adhesion kinase and proliferation by a
Ras-MAPK-mediated disinhibition of retinoblastoma protein (Danen
et al., 2000
; Sieg et al., 2000
; Davenpeck et al., 2001
). Thus, the
inhibition of fibronectin production by p38 MAPK inhibitors would be
expected to indirectly limit VSMCs differentiation, proliferation, and migration associated with vascular injury.
In conclusion, we have demonstrated that the sustained activation of
the p38 MAPK pathway plays an important role in neointima formation
associated with vascular injury, perhaps by mediating TGF-
-induced
fibronectin production. The present study also suggests that p38 MAPK
inhibitors represent a novel therapeutic approach to the treatment of
restenosis associated with coronary angioplasty.
| |
Acknowledgments |
|---|
We are indebted to Susan Tirri for excellent secretarial assistance and Wendy J. Crowell for help in preparing figures.
| |
Footnotes |
|---|
Accepted for publication December 17, 2001.
Received for publication September 14, 2001.
Address correspondence to: Dr. Robert N. Willette, Department of Cardiovascular Pharmacology, UW2510, GlaxoSmithKline, 709 Swedeland Road, Box 1539, King of Prussia, PA 19406-0939. E-mail: robert_n_willette{at}gsk.com
| |
Abbreviations |
|---|
VSMCs, vascular smooth muscle cells; MAPK, mitogen-activated protein kinase; IR, immunoreactivity; IL, interleukin; TNF, tumor necrosis factor; PCNA, proliferating cell nuclear antigen; PDGF, platelet-derived growth factor; FBS, fetal bovine serum; TGF, transforming growth factor; SB 239063, trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-[(2-methoxy)pyrimidin-4-yl]imidazole; FR167653, 1[7-(4-fluorophenyl)-1,2,3,4-tetrahydro-8-(4-pyridyl)pyrazolo[5,1-c][1,2,4]triazin-2-yl]-2-phenylethanedione sulfate monohydrate; RAM-11, rabbit anti-macrophage.
| |
References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
L. J. Sommerville, C. Xing, S. E. Kelemen, S. Eguchi, and M. V. Autieri Inhibition of allograft inflammatory factor-1 expression reduces development of neointimal hyperplasia and p38 kinase activity Cardiovasc Res, October 1, 2008; (2008) cvn242v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fu, M. J. Corbley, L. Sun, J. E. Friedman, F. Shan, J. L. Papadatos, D. Costa, F. Lutterodt, H. Sweigard, S. Bowes, et al. SM16, an Orally Active TGF-{beta} Type I Receptor Inhibitor Prevents Myofibroblast Induction and Vascular Fibrosis in the Rat Carotid Injury Model Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 665 - 671. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. B. Morris, A. R. Olzinski, R. E. Bernard, K. Aravindhan, R. C. Mirabile, R. Boyce, R. N. Willette, and B. M. Jucker p38 MAPK Inhibition Reduces Aortic Ultrasmall Superparamagnetic Iron Oxide Uptake in a Mouse Model of Atherosclerosis: MRI Assessment Arterioscler. Thromb. Vasc. Biol., February 1, 2008; 28(2): 265 - 271. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Y. Sung, H. Guan, A. Czibula, A. R. King, K. Eder, E. Heath, S. K. Suvarna, S. K. Dower, A. G. Wilson, S. E. Francis, et al. Human Tribbles-1 Controls Proliferation and Chemotaxis of Smooth Muscle Cells via MAPK Signaling Pathways J. Biol. Chem., June 22, 2007; 282(25): 18379 - 18387. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Khan, A. Agrotis, and A. Bobik Understanding the role of transforming growth factor-{beta}1 in intimal thickening after vascular injury Cardiovasc Res, May 1, 2007; 74(2): 223 - 234. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. T. Gerthoffer Mechanisms of Vascular Smooth Muscle Cell Migration Circ. Res., March 16, 2007; 100(5): 607 - 621. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Olzinski, T. A. McCafferty, S. Q. Zhao, D. J. Behm, M. E. Eybye, K. Maniscalco, R. Bentley, K. S. Frazier, C. M. Milliner, R. C. Mirabile, et al. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection Cardiovasc Res, April 1, 2005; 66(1): 170 - 178. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ott, B. Weigand, R. Michl, I. Seitz, N. Sabbari-Erfani, F.-J. Neumann, and A. Schomig Tissue Factor Cytoplasmic Domain Stimulates Migration by Activation of the GTPase Rac1 and the Mitogen-Activated Protein Kinase p38 Circulation, January 25, 2005; 111(3): 349 - 355. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, J. H. Kwak, S. I. Kim, Y. He, and M. E. Choi Transforming Growth Factor-{beta}1 Stimulates Vascular Endothelial Growth Factor 164 via Mitogen-activated Protein Kinase Kinase 3-p38{alpha} and p38{delta} Mitogen-activated Protein Kinase-dependent Pathway in Murine Mesangial Cells J. Biol. Chem., August 6, 2004; 279(32): 33213 - 33219. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Medeiros, D. A. Cabrini, J. Ferreira, E. S. Fernandes, M. A.S. Mori, J. B. Pesquero, M. Bader, M. C.W. Avellar, M. M. Campos, and J. B. Calixto Bradykinin B1 Receptor Expression Induced by Tissue Damage in the Rat Portal Vein: A Critical Role for Mitogen-Activated Protein Kinase and Nuclear Factor-{kappa}B Signaling Pathways Circ. Res., May 28, 2004; 94(10): 1375 - 1382. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Cornelissen, J. Armstrong, and C. M. Holt Mechanical Stretch Induces Phosphorylation of p38-MAPK and Apoptosis in Human Saphenous Vein Arterioscler. Thromb. Vasc. Biol., March 1, 2004; 24(3): 451 - 456. [Abstract] [Full Text] |
||||
![]() |
H. Ju, D. J. Behm, S. Nerurkar, M. E. Eybye, R. E. Haimbach, A. R. Olzinski, S. A. Douglas, and R. N. Willette p38 MAPK Inhibitors Ameliorate Target Organ Damage in Hypertension: Part 1. p38 MAPK-Dependent Endothelial Dysfunction and Hypertension J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 932 - 938. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Tfelt-Hansen, R. J. MacLeod, N. Chattopadhyay, S. Yano, S. Quinn, X. Ren, E. F. Terwilliger, P. Schwarz, and E. M. Brown Calcium-sensing receptor stimulates PTHrP release by pathways dependent on PKC, p38 MAPK, JNK, and ERK1/2 in H-500 cells Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E329 - E337. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Wang, R. Ma, R. A. Flavell, and M. E. Choi Requirement of Mitogen-activated Protein Kinase Kinase 3 (MKK3) for Activation of p38alpha and p38delta MAPK Isoforms by TGF-beta 1 in Murine Mesangial Cells J. Biol. Chem., November 27, 2002; 277(49): 47257 - 47262. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||